Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Finished Goods (2023 - 2024)

Harmony Biosciences Holdings' Finished Goods history spans 2 years, with the latest figure at $2.8 million for Q4 2024.

  • For Q4 2024, Finished Goods rose 21.11% year-over-year to $2.8 million; the TTM value through Dec 2024 reached $2.8 million, up 21.11%, while the annual FY2024 figure was $2.8 million, 21.11% up from the prior year.
  • Finished Goods for Q4 2024 was $2.8 million at Harmony Biosciences Holdings, down from $3.3 million in the prior quarter.
  • Across five years, Finished Goods topped out at $3.3 million in Q3 2024 and bottomed at $2.3 million in Q4 2023.